Artigo de periodico

Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score (2022)

• Authors:
  • Burtness, Barbara
  • Rischin, Danny
  • Greil, Richard
  • Soulieres, Denis
  • Tahara, Makoto
  • Castro Junior, Gilberto de Castro
  • Psyrri, Amanda
  • Brana, Irene
  • Baste, Neus
  • Neupane, Prakash
• Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
• Unidade: FM
• DOI: 10.1200/JCO.21.02198
• Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO; QUIMIOTERAPIA; CARCINOMA DE CÉLULAS ESCAMOSAS; METÁSTASE NEOPLÁSICA
• Agências de fomento:
  • Merck Sharp Dohme Corp
• Language: Inglês
• Imprenta:
  • Publisher place: Philadelphia
  • Date published: 2022
• Source:
  • Título: Journal of clinical oncology
  • ISSN: 0732-183X
  • Volume/Número/Paginação/Ano: v. 40, n. 21, p. 2321-2334, 2022


Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).

Status:

Artigo aberto em periódico híbrido (Hybrid Open Access)

Versão do Documento:

Versão publicada (Published version)

Acessar versão aberta:

• PDF de acesso aberto

Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, v. 40, n. 21, p. 2321-2334, 2022Tradução . . Disponível em: https://doi.org/10.1200/JCO.21.02198. Acesso em: 07 maio 2026.

• APA

  Burtness, B., Rischin, D., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, 40( 21), 2321-2334. doi:10.1200/JCO.21.02198

• NLM

  Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2026 maio 07 ] Available from: https://doi.org/10.1200/JCO.21.02198

• Vancouver

  Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2026 maio 07 ] Available from: https://doi.org/10.1200/JCO.21.02198

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Non-gastrointestinal stromal tumours soft tissue sarcomas: an update
• Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
• Epidemiologia do câncer de pulmão
• Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
• Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus
• The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer
• Desenvolvimento de fármacos: pesquisa clínica e medicina de precisão
• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
• Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
• Real-World molecular testing and treatment patterns in brazilian patients with newly diagnosed locally advanced or metastatic NSCLC